Stephanie Gaillard | Scholars@Duke

Stephanie Gaillard
Adjunct Assistant Professor in the Department of Medicine

Dr. Stéphanie Gaillard is an Assistant Professor in Medical Oncology at the Duke Cancer Institute. Dr. Gaillard is board certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. At Duke, she focuses on treating patients with gynecologic malignancies and conducts basic science and clinical research. Dr. Gaillard’s laboratory research focuses on elucidating the biology of ovarian cancer, especially metabolic changes in the development of ovarian tumors, and mechanisms of resistance to chemotherapy. Her clinical research interests center on the development of novel therapeutic strategies for the treatment of ovarian cancer through early phase clinical trials. In addition to the Ovarian Cancer Research Fund Liz Tilberis Grant, Dr. Gaillard has received a Department of Defense Breast Cancer Research Program pre-doctoral research award and a Conquer Cancer Foundation Young Investigator Award.

Current Appointments & Affiliations

Adjunct Assistant Professor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2017

Contact Information

2000B Burdock Rd, Baltimore, MD 21209
DUMC 3079, Durham, NC 27710
stephanie.gaillard@duke.edu (919) 423-1363

Background
Education, Training, & Certifications
- Medical Oncology Fellowship, Johns Hopkins University School of Medicine 2009 - 2012
- Internal Medicine Internship and Residency, Johns Hopkins University School of Medicine 2006 - 2009
Duke Appointment History
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2013 - 2018
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2012 - 2017
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Yu, Y, Suryo Rahmanto, Y, Lee, M-H, Wu, P-H, Phillip, JM, Huang, C-H, Vitolo, MI, Gaillard, S, Martin, SS, Wirtz, D, Shih, I-M, and Wang, T-L. "Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway." Oncogene 37, no. 28 (July 2018): 3778-3789. Full Text
  - Asaka, S, Yen, TT, Wang, TL, Shih, IM, and Gaillard, S. "T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers(Accepted)." Modern Pathology (January 1, 2018). Full Text
  - Fader, AN, Bergstrom, J, Jernigan, A, Tanner, EJ, Roche, KL, Stone, RL, Levinson, KL, Ricci, S, Wethingon, S, Wang, T-L, Shih, I-M, Yang, B, Zhang, G, Armstrong, DK, Gaillard, S, Michener, C, DeBernardo, R, and Rose, PG. "Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?." Gynecologic oncology 147, no. 1 (October 2017): 85-91. Full Text
  - Chan, JK, Deng, W, Higgins, RV, Tewari, KS, Bonebrake, AJ, Hicks, M, Gaillard, S, Ramirez, PT, Chafe, W, Monk, BJ, and Aghajanian, C. "A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study." Gynecologic oncology 146, no. 3 (September 2017): 554-559. Full Text
  - Hong, JC, Foote, J, Broadwater, G, Gaillard, S, Havrilesky, LJ, and Chino, JP. "Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 27, no. 4 (May 2017): 720-729. Full Text
  - Gaillard, SL, Secord, AA, and Monk, B. "The role of immune checkpoint inhibition in the treatment of ovarian cancer." Gynecologic Oncology Research and Practice 3 (January 2016): 11-null. (Review) Full Text
  - Yu, Y, Gaillard, S, Phillip, JM, Huang, T-C, Pinto, SM, Tessarollo, NG, Zhang, Z, Pandey, A, Wirtz, D, Ayhan, A, Davidson, B, Wang, T-L, and Shih, I-M. "Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules." Cancer cell 28, no. 1 (July 2015): 82-96. Full Text
  - Havrilesky, LJ, Alvarez Secord, A, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, SL, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP, and Reed, SD. "Patient preferences in advanced or recurrent ovarian cancer." Cancer 120, no. 23 (December 2014): 3651-3659. Full Text
  - Martin, LP, Sill, M, Shahin, MS, Powell, M, DiSilvestro, P, Landrum, LM, Gaillard, SL, Goodheart, MJ, Hoffman, J, and Schilder, RJ. "A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study." Gynecologic Oncology 132, no. 3 (March 2014): 526-530. Full Text
  - Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, SL, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP, and Reed, SD. "Patient preferences in advanced or recurrent ovarian cancer." Cancer 120, no. 23 (January 1, 2014): 3651-3659. Full Text
  - Martin, LP, Sill, M, Shahin, MS, Powell, M, Disilvestro, P, Landrum, LM, Gaillard, SL, Goodheart, MJ, Hoffman, J, and Schilder, RJ. "A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study." Gynecologic Oncology 132, no. 3 (January 1, 2014): 526-530. Full Text
  - Gaillard, S, and Stearns, V. "Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management." Breast Cancer Research : Bcr 13, no. 2 (March 14, 2011): 205-null. (Review) Full Text
  - Gaillard, S, Dinoso, JB, Marsh, JA, DeZern, AE, O'Connell, KA, Spivak, AM, Alwood, K, Durand, CM, Ambinder, RF, and Blankson, JN. "Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy." Journal of Clinical Virology 51, no. 3 (2011): 195-198. Full Text
  - Gaillard, S, and Armstrong, D. "Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: Many questions, much promise&amp." Oncology 25, no. 2 (2011).
  - Grasfeder, LL, Gaillard, S, Hammes, SR, Ilkayeva, O, Newgard, CB, Hochberg, RB, Dwyer, MA, Chang, C-Y, and McDonnell, DP. "Fasting-induced hepatic production of DHEA is regulated by PGC-1alpha, ERRalpha, and HNF4alpha." Mol Endocrinol 23, no. 8 (August 2009): 1171-1182. Full Text Link to Item
  - Stein, RA, Gaillard, S, and McDonnell, DP. "Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells." The Journal of Steroid Biochemistry and Molecular Biology 114, no. 1-2 (March 3, 2009): 106-112. Full Text
  - Gaillard, S, and Wondisford, FE. "Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor." Clinical Management of Thyroid Disease (2009): 81-101. Full Text
  - Gaillard, S, Dwyer, MA, and McDonnell, DP. "Definition of the molecular basis for estrogen receptor-related receptor-alpha-cofactor interactions." Molecular Endocrinology (Baltimore, Md.) 21, no. 1 (January 2007): 62-76. Full Text
  - Gaillard, S, Grasfeder, LL, Haeffele, CL, Lobenhofer, EK, Chu, T-M, Wolfinger, R, Kazmin, D, Koves, TR, Muoio, DM, Chang, C-Y, and McDonnell, DP. "Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs." Mol Cell 24, no. 5 (December 8, 2006): 797-803. Full Text Link to Item
  - Zhang, Y, Ma, K, Sadana, P, Chowdhury, F, Gaillard, S, Wang, F, McDonnell, DP, Unterman, TG, Elam, MB, and Park, EA. "Estrogen-related receptors stimulate pyruvate dehydrogenase kinase isoform 4 gene expression." The Journal of Biological Chemistry 281, no. 52 (December 2006): 39897-39906. Full Text
  - Chao, EYH, Collins, JL, Gaillard, S, Miller, AB, Wang, L, Orband-Miller, LA, Nolte, RT, McDonnell, DP, Willson, TM, and Zuercher, WJ. "Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma." Bioorganic & Medicinal Chemistry Letters 16, no. 4 (February 2006): 821-824. Full Text
  - Safi, R, Kovacic, A, Gaillard, S, Murata, Y, Simpson, ER, McDonnell, DP, and Clyne, CD. "Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy." Cancer Res 65, no. 24 (December 15, 2005): 11762-11770. Full Text Link to Item
  - Kovacs, JJ, Murphy, PJM, Gaillard, S, Zhao, X, Wu, J-T, Nicchitta, CV, Yoshida, M, Toft, DO, Pratt, WB, and Yao, T-P. "HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor." Molecular Cell 18, no. 5 (May 2005): 601-607. Full Text
  - Zuercher, WJ, Gaillard, S, Orband-Miller, LA, Chao, EYH, Shearer, BG, Jones, DG, Miller, AB, Collins, JL, McDonnell, DP, and Willson, TM. "Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma." Journal of Medicinal Chemistry 48, no. 9 (May 2005): 3107-3109. Full Text
- Book Sections
  - Gaillard, S, Maxwell, GL, Sood, AK, and Berchuck, A. "Biology and genetics." In Berek and Hacker's Gynecologic Oncology: Sixth Edition, 2-38. November 11, 2014.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Publications

Academic Articles

Book Sections